TCGX Acquisition Corp. II has priced its initial public offering of 10,000,000 Class A ordinary shares at $10.00 per share, generating gross proceeds of $100,000,000. The Palo Alto-based special purpose acquisition company announced the pricing on October 15, 2026, distinguishing its structure from other SPAC offerings by not including warrants that would become exercisable upon the completion of an initial business combination.
The Class A ordinary shares are scheduled to begin trading on The Nasdaq Capital Market under the ticker symbol "TCXB" on October 16, 2026. The company expects the offering to close on or about October 19, 2026, subject to customary closing conditions. Guggenheim Securities is serving as the sole book-running manager for the deal, which does not include an over-allotment option.
TCGX Acquisition Corp. II was formed to pursue a strategic combination with one or more target businesses through methods such as a merger, asset purchase, or reorganization. While the company may pursue opportunities in any industry or geographical location, it intends to focus its search on the healthcare and healthcare-related industries, specifically within the life sciences and medical technology sectors. The entity is sponsored by TCGX Sponsor II, LLC, an affiliate of TCG Crossover Management, LLC.
The Securities and Exchange Commission declared the registration statement for these securities effective on October 15, 2026. The offering is being made only by means of a prospectus, with copies available from Guggenheim Securities, LLC in New York. The company noted that no assurance can be given that the proceeds will be used as indicated and that forward-looking statements regarding its search for a business combination are subject to conditions beyond its control.
Investors interested in the offering must obtain the prospectus from Guggenheim Securities or by contacting their Equity Syndicate Department. The press release states that it does not constitute an offer to sell securities or a solicitation of an offer to buy in any jurisdiction where such activity would be unlawful prior to registration or qualification under applicable securities laws.